MicroRNA-141 inhibits migration of gastric cancer by targeting zinc finger E-box-binding homeobox 2

YING DU¹, LINGFEI WANG², HONGHAI WU³, YIYIN ZHANG⁴, KAN WANG⁴ and DINGTING WU⁴

¹Department of Endocrinology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016; ²Department of Pharmacy, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009; ³Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang 310058; ⁴Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China

Received August 10, 2014; Accepted April 15, 2015

DOI: 10.3892/mmr.2015.3789

Abstract. Human microRNA (miR)-141 is a member of the miR-200 family, which has been reported to be downregulated in gastric cancer, and involved in the proliferation of gastric cancer cells. However, little is currently known regarding its role in the migration of gastric cancer. The present study investigated the function of miR-141 in gastric cancer cell migration, and evaluated the contribution of zinc finger E-box-binding homeobox 1 and 2 (ZEB1/2) in miR-141 mediated migration of gastric cancer cells. The expression levels of miR-141 and its potential ZEB1/2 targets were examined by quantitative polymerase chain reaction (qPCR) and western blotting, respectively. The migration of SGC-7901 and HGC-27 gastric cancer cells, which had been transfected with an miRNA precursor, was examined by cell migration and wound healing assays. A luciferase activity assay was used to validate whether ZEB1/2 was a direct target of miR-141. The results demonstrated that overexpression of miR-141 markedly inhibited the migration of gastric cancer cells in vitro. Forced overexpression of miR-141 significantly reduced the luciferase activity of the 3'-untranslated region of ZEB2 in gastric cancer cells. Furthermore, the mRNA and protein expression levels of ZEB2 were reduced in cells overexpressing miR-141, whereas the protein expression levels of E-cadherin were increased. In gastric tumor samples the expression levels of ZEB2 were inversely correlated with the expression of miR-141. These results suggest that miR-141 may be involved in the inhibition of gastric cancer cell migration, and that ZEB2 is a target gene of miR-141.

Introduction

Gastric cancer is the fourth most common type of cancer and the second most frequent cause of cancer-associated mortality worldwide (1). The global age-standardized mortality rates are 14.3 per 100,000 in men, and 6.9 per 100,000 in women (2). In 2013, the estimated number of new cases of stomach cancer in the United States reached 21,600, with a mortality rate of ~10,990 (3). Despite recent advances in the diagnosis and treatment of gastric cancer, the majority of patients are diagnosed with advanced gastric cancer, and the survival rate remains unsatisfactory. Invasion and metastasis are the hallmarks of advanced gastric cancer progression; therefore, understanding the pathogenesis of gastric cancer metastasis is critical to improve the survival rate of patients.

Micro (mi)RNAs are a class of short, non-coding RNAs which have been reported to be involved in numerous physiological processes, and to have important roles in diseases such as cancer (4). Each miRNA can target numerous genes, either by degradation of mRNAs or by inhibition of translation. In cancer, miRNAs have been identified to target oncogenes or tumor suppressors, and therefore may positively or negatively regulate cancer cell proliferation, migration, and invasion (4,5). In gastric adenocarcinoma, overexpression of miR-181a has been shown to increase cell proliferation and to inhibit apoptosis by reducing the expression of tumor suppressor Krueppel-like factor 6 (6). In addition, miR-375 is downregulated in gastric cancer and its overexpression inhibits cancer cell proliferation by targeting the oncogene Janus kinase 2 (7).

miR-141 is a member of the miR-200 family, which has been shown to be downregulated in gastric tumor tissue. In addition, overexpression of miR-141 significantly reduces the proliferation of gastric cancer cells (8). Notably, it has been demonstrated that miR-141 may inhibit cell migration and invasion in colorectal, pancreatic, and hepatocellular carcinoma (9-11). Therefore, the present study hypothesized that miR-141 may also have a role in the migration of gastric cancer cells.

Epithelial to mesenchymal transition (EMT) is a fundamental biological disease process, during which polarized
immotile epithelial cells are converted to motile mesenchymal cells. EMT can lead to tumor invasion and metastasis (12,13). The zinc finger E-box-binding homeobox, including ZEB1 and ZEB2, inhibits the translation of E-cadherin, the loss of which is a marker of EMT. The miR-200 family has previously been reported to suppress EMT through translational inhibition of ZEB mRNA in various types of cancer (14). miR-141 has been shown to exclusively target ZEBs in renal, colorectal, and head and neck squamous carcinoma cells (9,15,16). Therefore, the present study aimed to determine whether miR-141 targets ZEB in gastric cancer, and whether it regulates the migration of cancer cells.

Materials and methods

Clinical samples and cell lines. A total of 18 gastric mucosa samples, including 9 non-malignant mucosa and 9 malignant mucosa samples, were obtained by gastroscopy from the Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (Hangzhou, China). Written informed consent was obtained from the patients prior to collection, and the study was approved by the Ethics Committee of the Sir Run Run Shaw Hospital School of Medicine Zhejiang University. Patient information is shown in Table I. All of the samples were immediately frozen and stored in liquid nitrogen for RNA analysis. Histopathological investigation was performed by two professional pathologists independently. Other clinical data were obtained from medical records within the Sir Run Run Shaw Hospital School of Medicine Zhejiang University. Patient information is shown in Table I. All of the samples were immediately frozen and stored in liquid nitrogen for RNA analysis. Histopathological investigation was performed by two professional pathologists independently. Other clinical data were obtained from medical records within the Sir Run Run Shaw Hospital School of Medicine Zhejiang University.

RNA extraction and reverse transcription-quantitative (RT-q)PCR. Tissue samples were homogenized manually in liquid nitrogen then immediately transferred to TRIzol reagent (Ambion Life Technologies). The total RNA was isolated from the tissue samples and cell lines using the mirVana miRNA Isolation kit (Ambion Life Technologies). Mature miRNAs were reverse transcribed using the TaqMan® MicroRNA reverse transcription kit (Applied Biosystems Life Technologies, Foster City, CA, USA). The HGC-27 human gastric cancer cells (Shanghai Institutes for Biological Sciences) were maintained in Dulbecco's modified Eagle's medium (Invitrogen Life Technologies). All media were supplemented with 10% fetal bovine serum (Gibco-BRL, Gaithersburg, MD, USA). Cells were maintained in a humidified atmosphere with 5% CO2 at 37°C.

Construction of plasmids. The putative miR-141-binding sites in the ZEB2 3'-untranslated region (UTR) region were detected using Targetscan software (http://www.targetscan.org). To produce the pMIR-ZEB2 plasmid, the human ZEB2 3'-UTR was amplified by polymerase chain reaction (PCR) using the following primers: Forward 5'-ATG TGC TCG CAC TAC AATGC-3', and reverse 5'-ATT GGT ACC AGT CAA AAT TAT TGC-3' (GenePharma Co., Ltd., Shanghai, China) prior to being cloned into a pMIR-REPORT vector (Ambion Life Technologies, Carlsbad, CA, USA). The mutation on the miR-141-binding sites in human ZEB2 3'-UTR was amplified by polymerase chain reaction (PCR) using the following primers: Forward 5'-AGCTT CATTC TTGAG CTCACC-3' and reverse 5'-GGTGAG CTTCAA GAATG AAGCT-3'. All constructs were confirmed by sequencing.

Table I. Patient information.

| No. | Sample   | Age | Gender | TNM      | AJCC Stage | Differentiation | Recruitment Date |
|-----|----------|-----|--------|----------|------------|-----------------|-----------------|
| 1   | Tumor    | 61  | M      | T4aN3aM0 | IIIC       | Low             | Oct 24, 2013    |
| 2   | Tumor    | 60  | M      | T4aN3bM0 | IIIC       | Low             | Nov 19, 2013    |
| 3   | Tumor    | 71  | F      | T1bN0M0  | IA         | Low             | Dec 1, 2013     |
| 4   | Tumor    | 63  | F      | T4aN0M0  | IIB        | Low             | Dec 1, 2013     |
| 5   | Tumor    | 52  | M      | T4aN3bM0 | IIIC       | Low             | Dec 24, 2013    |
| 6   | Tumor    | 70  | F      | T4aN3aM0 | IIC        | Moderate        | Dec 25, 2013    |
| 7   | Tumor    | 83  | F      | T4aN0M0  | IIB        | Low             | Dec 25, 2013    |
| 8   | Tumor    | 64  | F      | T4aNxM1  | IV         | Low             | Dec 25, 2013    |
| 9   | Tumor    | 70  | F      | T4aN0M0  | IIB        | Low             | Jan 9, 2014     |
| 10  | Non-tumor| 66  | M      | None     | None       | None            | Oct 23, 2013    |
| 11  | Non-tumor| 66  | F      | None     | None       | None            | Oct 23, 2013    |
| 12  | Non-tumor| 51  | F      | None     | None       | None            | Oct 24, 2013    |
| 13  | Non-tumor| 53  | F      | None     | None       | None            | Oct 31, 2013    |
| 14  | Non-tumor| 45  | M      | None     | None       | None            | Oct 31, 2013    |
| 15  | Non-tumor| 41  | F      | None     | None       | None            | Nov 12, 2013    |
| 16  | Non-tumor| 38  | F      | None     | None       | None            | Dec 13, 2013    |
| 17  | Non-tumor| 30  | M      | None     | None       | None            | Dec 24, 2013    |
| 18  | Non-tumor| 48  | F      | None     | None       | None            | Dec 24, 2013    |

TNM and Cancer Stage are defined according to the 7th edition of the AJCC cancer staging manual published in 2010. TNM, tumor, lymph node, metastasis; F, female; M, male; AJCC, American Joint Committee on Cancer.
City, CA, USA), and qPCR was performed using TaqMan microRNA assays with specific primers for hsa-miR-141 (P/N, 4373137; Applied Biosystems Life Technologies). qPCR was performed on the Applied Biosystems 7500 Real-Time PCR systems (Applied Biosystems). The cycling conditions were as follows: 95°C for 30 sec, annealing at 60°C for 30 sec then 72°C for 30 sec for 30 cycles then maintained at 4°C until further analysis. Comparative qPCR was performed in triplicate, including non-template controls. All data was normalized to U6 expression (P/N, 4373381, Applied Biosystems). Fold change was determined as 2ΔΔCt and miR-141 expression in endoscopic samples was also normalized to U6 expression using the 2ΔΔCt method (18).

Cell transfection. To determine the effects of miR-141 on cell proliferation, 5x10^4 SGC-7901 and HGC-27 cells were transfected with either a 25 nM Pre-miR™ miR-141 precursor molecule (miR-141; Ambion Life Technologies), or a negative control #1 Pre-miR™ miRNA precursor molecule (Negative; Ambion Life Technologies), using siPORT™ Amine Transfection Agent (Ambion Life Technologies) in a 96-well plate. The expression of miR-141 was detected by qPCR 24 h post-transfection. An MT assay was performed at 24 h post-transfection. Cells were seeded into 96-well plates containing a final volume of 100 µl/well and treated with the miRNA as indicated. Subsequently, 10 µl MTT solution (Bio Basic Inc., Amherst, NY, USA) was added per well to achieve a final concentration of 0.45 mg/ml. Following incubation for 2 h at 37°C, 100 µl solubilization solution was added to each well to dissolve formazan crystals. The absorbance of the samples was measured using a spectrophotometer reader (Multiskan FC 51119000, Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 490 nm. Each assay was performed in triplicate and repeated three times.

Cell migration assay. A Boyden chamber system (Costar, Corning, Inc., Tewkesbury, MA, US) was used for the transwell migration assay. The SGC-7901 and HGC-27 cells (5x10^4) were transfected with either 25 nM miR-141 or negative control in 24-well plates for 24 h. The cells were then trypsinized and 10^5 cells were seeded into each insert in culture medium, and the same medium was placed in the well below. Following a 24 h incubation period, the cells remaining in the top inserts were removed using a cotton swab, and the cells that had migrated through the filter were fixed with 75% ethanol for 30 min, followed by 0.1% crystal violet staining (Sigma-Aldrich, St. Louis, MO, USA) for 20 min. The ability of the cells to migrate to the lower chamber was visualized, and the images were captured using an inverted microscope (Leica DMI 4000B, Leica Microsystems, Wetzlar, Germany).

Wound healing assay. Approximately 5x10^4 cells were seeded in 24-well plates and cultured until 70-80% confluent. The cells were transfected with miR-141 and controls as previously described. Wounds were established using a p20 pipet tip and the cells were allowed 24 h to migrate into the wounds. To assess the migration of the cells across the artificial wound, a total of five optical fields (magnification, x10) were randomly selected and analyzed using a Leica DMI 4000B inverted microscope with the Leica application suite software (Leica Microsystems).

Western blot analysis. Protein samples were extracted using the Total protein extraction kit (Beyotime Institute of Biotechnology, Shanghai, China). Protein concentrations were quantified using a Lowry protein assay kit (Majorbio Biotech Co., Ltd., Shanghai, China). Protein samples were size-fractionated by 10% SDS-PAGE using 10 µg protein and then transferred to polyvinylidene difluoride membranes (EMD Millipore, Bedford, MA, USA). The blots were blocked for 1 h in 5% milk/Tris-buffered saline-0.1% Tween 20 (TBS-T), and then incubated with primary antibodies at 4°C overnight. The blots were then washed three times for 15 min with TBS-T, followed by incubation with the secondary antibodies in 5% milk/TBS-T for 1 h, and then washed three times for 15 min with TBS-T. The membranes were briefly incubated with enhanced chemiluminescence detection reagent (GE Healthcare, Pittsburgh, PA, USA) to visualize the proteins, and then exposed in a cassette to an X-ray film (Carestream Health, Inc, Shanghai, China) for several minutes. The blots were quantified using Quantity One 1-D analysis software, version 4.62 (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

The primary antibodies used were as follows: Anti-E-cadherin (cat no. 610405), purchased from BD Biosciences (Franklin Lakes, NJ, USA), and anti-β-actin (cat no. sc-47778), anti-ZEB1 (cat no. sc-25388) and anti-ZEB2 (cat no. sc-48789), which were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). The secondary antibodies used were as follows: Goat anti-mouse IgG HRP (cat. no. 2A-10004302-1), goat anti-rabbit IgG HRP (cat. no. 2A-10004301-1) (Cayman Chemical, Ann Arbor, MI, USA) and rabbit anti-goat IgG HRP (cat. sc. NC-2768; Santa Cruz Biotechnology Inc.).

Luciferase activity assay. A total of 4x10^4 cells were seeded in 24-well plates 24 h prior to transfection. The cells were cotransfected with 0.1 µg of either pMIR-ZEB2 or pMIR-REPORT, together with 20 nM miR-141 precursor molecule or 20 nM negative control #1 using siPORT amine transfection agent, according to the manufacturer's instructions. The pRL-TK vector (Promega Corp., Madison, WI, USA) containing Renilla luciferase was also cotransfected as a reference control. Firefly and Renilla luciferase activities were measured using Dual-Luciferase Reporter assay (Promega Corp.) 24 h post-transfection. The luciferase activity was measured using a luminometer (GloMax™ 96 Microplate Luminometer, Promega Corp.). Firefly luciferase activity was normalized to Renilla luciferase activity.

Statistical analysis. The data are expressed as the mean ± standard error. Student's t-test was applied to analyze the differences between the groups, and statistical analysis was performed using SPSS software version 13 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Effects of miR-141 overexpression on the migration of gastric cancer cells. To explore the effects of miR-141 on the migration of gastric cancer cells, two human gastric mucous adenocarcinoma cell lines, HGC-27 and SGC-7901,
were transfected with an miR-141 precursor or negative control precursor. The expression levels of miR-141 were upregulated by ~335 and 252 fold respectively in the HGC-27 and SGC-7901 cells transfected with miR-141 precursor, as compared with the control cells (Fig. 1A). The proliferation of both cell lines was not affected by miR-141 overexpression, as determined by MTT assay (Fig. 1B) over 24 h. The in vitro migration assay (Fig. 1C and D) and wound healing assay (Fig. 1E and F) demonstrated that overexpression of miR-141 markedly inhibited the migration of HGC-27 and SGC-7901 cells.

**ZEB2 is a target of miR-141.** To determine whether ZEBs are a target of miR-141 in gastric cancer, alterations in ZEB1/2 expression levels were determined post-transfection with an miR-141 precursor. As shown in Fig. 2, forced expression of miR-141 significantly reduced ZEB1/2 mRNA and protein expression levels in both HGC-27 and SGC-7901 gastric cancer cells. Conversely, overexpression of miR-141 upregulated the protein expression level of E-cadherin in both cell lines (Fig. 2C).

To further confirm whether ZEB1/2 is directly regulated by miR-141, the 3’-UTR of ZEB2 was cloned with the predicted miR-141 binding sites downstream of a luciferase reporter gene (pMIR-ZEB2), and this vector was co-transfected with the miR-141 precursor or its negative control into HGC-27 and SGC-7901 cells. The luciferase activity of cells transfected with the miR-141 precursor was significantly decreased compared with the negative control. Furthermore, mutation of the putative miR-141-binding sites clearly eliminated the suppression of luciferase activity caused by miR-141 overexpression (Fig. 3A, B and C). These data suggest that miR-141 may inhibit ZEB2 protein expression through 3’-UTR at the posttranscriptional level.

**Expression of ZEB2 is inversely correlated with miR-141.** The mRNA expression levels of miR-141 and ZEB2 were detected in nine gastric tumor and non-tumor tissues by qPCR. The expression levels of miR-141 were significantly decreased in the gastric tumor tissue samples, compared with in the non-tumor tissue samples (Fig. 4A); however, mRNA expression levels
Figure 2. Effects of microRNA (miR)-141 on the expression levels of zinc finger E-box-binding homeobox (ZEB) in HGC-27 and SGC-7901 gastric cancer cells. The cells were transfected with miR-141 precursor (25 nM), negative control (Negative, 25 nM) or neither of the above (Control), and were subjected to quantitative polymerase chain reaction (qPCR) and western blotting. mRNA expression levels of ZEB1/2 were measured by qPCR in (A) HGC-27 and (B) SGC-7901 cells 24 h post-transfection. Data are expressed as the mean ± standard error from three independent experiments. *P<0.05, vs. Negative. (C) Protein expression levels of ZEB1/2 and E-cadherin were detected by western blot analyses in HGC-27 and SGC-7901 cells. The expression of actin was used as a loading control.

Figure 3. Zinc finger E-box-binding homeobox 2 (ZEB2) is the target of microRNA (miR)-141. (A) Schematic diagram of the putative miR-141-binding sites in the ZEB2 3'-untranslated region (UTR) region, as detected by TargetScan. ZEB2-mut indicates the ZEB2 3' UTR with mutation in miR-141-binding sites. (B and C) Regulation of luciferase activity by ZEB2 3'-UTR is dependent on miR-141. (B) HGC-27 and (C) SGC-7901 human gastric cancer cells were transfected with the pRL-TK containing a Renilla luciferase gene, and the indicated vectors or precursors. Bars indicate the Firefly luciferase activities normalized to Renilla luciferase activities of the cotransfected pRL-TKvector. Each experiment was repeated at least three times, and each sample was assayed in triplicate. Data is expressed as the mean ± standard error from three independent experiments. *P<0.05, vs. Negative.
of ZEB2 were increased in the gastric cancer tissue samples (Fig. 4B). The results suggest that the mRNA expression levels of ZEB2 may be inversely correlated with the expression levels of miR-141 in gastric tumor samples.

Discussion

Numerous miRNAs have been reported to be involved in gastric cancer development (19). In our previous study, miR-141, which belongs to the miR-200 family, was shown to be downregulated in gastric cancer tissue samples and cell lines. In addition, upregulation of miR-141 significantly inhibited gastric cancer cell proliferation (8). The present study provided evidence suggesting that transfection with an miR-141 precursor suppresses the migration of gastric cancer cells. Overexpression of miR-141 significantly reduced the mRNA and protein expression levels of ZEB2, resulting in the upregulation of E-cadherin expression. By using a luciferase reporter assay, it was demonstrated that ZEB2 was the target of miR-141 in gastric cancer cell lines. Furthermore, the mRNA expression levels of ZEB2 mRNA were inversely correlated with the levels of miR-141 in gastric cancer tissue. The results of the present study suggest that miR-141 may have an important role in the inhibition and migration of gastric cancer cells, by targeting ZEB2.

miR-141 has previously been shown to function as a tumor suppressor in various cancers (9-11,16,20). It has been reported that low expression of miR-141 is a significant prognostic factor for poor overall survival, both in hepatocellular carcinoma (HCC) (10) and pancreatic cancer (PC) (20). Upregulation of miR-141 resulted in a significant decrease in the migration and invasiveness of HCC and PC cancer cells (10,11,20). Similar findings have been obtained for colorectal cancer (CRC), as well as head and squamous cell carcinoma (9,16), indicating that miR-141 functions as an inhibitor of cancer metastasis by decreasing the migration and invasive potential of cancer cells. In our previous study, it was demonstrated that the expression levels of miR-141 in HGC-25 and SGC-7901 gastric cancer cell lines were lower as compared to that of MGC-803 poorly-differentiated human gastric mucous adenocarcinoma and BGC-823 undifferentiated human gastric cancer cell lines. Notably, both HGC-27 and SGC-7901 cells are derived from metastatic lymph nodes and are comparatively more invasive than the other two cell lines (8), which prompted us to evaluate the potential function of miR-141 in the metastasis of gastric cancer cells. The present study used HGC-27 and SGC-7901 cells as an in vitro model, and demonstrated that forced expression of miR-141 markedly inhibited the migration of gastric cancer cells.

The targets by which miR-141 regulates cancer cell motility varies in different types of cancer. miR-141 has been shown to inhibit the migration and invasion of HCC cells by targeting Tiam1 (10). In PC, both transmembrane 4 L six family member 1 and MAP4K4 have been reported to be directly targeted by miR-141 to regulate the invasion of PC cells (11,20). Chen et al (21) identified hepatoma-derived growth factor (HDGF) as a direct target of miR-141 in gastric cancer cells, and the suppressive effects of miR-141 on cancer cell migration and invasion were shown to be partially mediated by suppression of HDGF expression. The results of the present study demonstrated that ZEB2 was another direct target of miR-141.

ZEB2 is one of the transcriptional suppressors of E-cadherin, which is a key regulator of EMT. EMT constitutes an early and critical step during tumor invasion and metastasis, and loss of E-cadherin is considered a hallmark of EMT (22). During EMT, the expression of the miR-200 members, including miR-141, has been shown to be significantly downregulated (14,23). Overexpression of miR-141 inhibits EMT by directly targeting the ZEBs and enhancing E-cadherin expression (14,23,24). In CRC cells, miR-141 was shown to regulate ZEB2, and inhibit the migration and invasion of CRC cells (9). In renal carcinoma cell lines, overexpression of miR-141 resulted in downregulation of ZEB2 and upregulation of E-cadherin (15). Recently, Wu et al (25) demonstrated that miR-141 functioned as a tumor suppressor via ZEB2 targeting HCC. Therefore, the present study hypothesized that in gastric cancer, downregulation of miR-141 may promote EMT, cancer cell migration, and invasion by targeting the E-cadherin transcriptional repressor ZEB2. However, further studies are required.

In conclusion, the present study demonstrated that overexpression of miR-141 inhibited gastric cancer cell migration. The miR-141 target ZEB2 was negatively regulated at both the transcriptional and post-transcriptional level by miR-141. These results suggest that miR-141 may suppress the
metastasis of gastric cancer through its inhibitory effect on the EMT process. It may be interesting to further explore whether miR-141 could be used as a predictive biomarker for clinical outcomes, or as a therapeutic target to prevent gastric cancer progression.

Acknowledgements

The present study was supported by a grant from the Zhejiang Provincial Nature Science Foundation of China (grant no. LQ12H16010).

References

1. Shen L, Shan YS, Hu HM, et al: Management of gastric cancer in Asia: Resource-stratified guidelines. Lancet Oncol 14: e535-e547, 2013.
2. Thrumurthy SG, Chaudry MA, Hochhauser D and Mughal M: The diagnosis and management of gastric cancer. BMJ 347: f6367, 2013.
3. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
4. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714, 2009.
5. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
6. Zhang X, Nie Y, Du Y, Cao J, Shen B and Li Y: MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6. Tumour Biol 33: 1589-1597, 2012.
7. Ding L, Xu Y, Zhang W, et al: MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 20: 784-793, 2010.
8. Du Y, Xu Y, Ding L, et al: Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol 44: 556-561, 2009.
9. Hu M, Xia M, Chen X, et al: MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. Dig Dis Sci 55: 2365-2372, 2010.
10. Liu Y, Ding Y, Huang J, et al: MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One 9: e88393, 2014.
11. Xu L, Li Q, Xu D, et al: hsa-miR-141 downregulates TM4SF1 to inhibit pancreatic cancer cell invasion and migration. Int J Oncol 44: 459-466, 2014.
12. Gregory PA, Bracken CP, Bert AG and Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7: 3112-3118, 2008.
13. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
14. Korpal M, Lee ES, Hu G and Kang Y: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283: 14910-14914, 2008.
15. Nakada C, Matsuura K, Tsukamoto Y, et al: Genome-wide microRNA expression profiling in renal cell carcinoma: Significant down-regulation of miR-141 and miR-200c. J Pathol 216: 418-427, 2008.
16. Tamagawa S, Beder LB, Hotomi M, et al: Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. Int J Mol Med 33: 879-886, 2014.
17. Zhou T, Zimmerman W, Liu X and Erikson RL. A mammalian NudC-like protein essential for dynein stability and cell viability. Proc Natl Acad Sci USA 103: 9039-9044, 2006.
18. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(2-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
19. Song S and Ajani JA. The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol 10: 109-118, 2013.
20. Zhao G, Wang B, Liu Y, et al: miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Mol Cancer Ther 12: 2569-2580, 2013.
21. Chen B, Huang T, Jiang J, Lv L, Li H and Xia S: miR-141 suppresses proliferation and motility of gastric cancer cells by targeting HDGF. Mol Cell Biochem 388: 211-218, 2014.
22. Larue L and Bellacosa A: Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3’ kinase/AKT pathways. Oncogene 24: 7443-7454, 2005.
23. Gregory PA, Bert AG, Paterson EL, et al: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601, 2008.
24. Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428, 2007.
25. Wu SM, Ai HW, Zhang DY, et al: MiR-141 targets ZEB2 to suppress HCC progression. Tumour Biol 35: 9993-9997, 2014.